Scholar Rock Holding (SRRK) Income from Continuing Operations (2017 - 2026)
Scholar Rock Holding (SRRK) recorded quarterly Income from Continuing Operations of 101383000.0 in Q1 2026, down 11.53% quarter-over-quarter from 90904000.0 in Q4 2025, and down 35.76% on a YoY basis from 157815134.07 in Q1 2025.
Scholar Rock Holding (SRRK) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 101383000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 35.76% year-over-year to 101383000.0; the TTM figure through Mar 2026 stood at 404342000.0 (down 53.13% YoY), while the FY2025 annual figure was 205000.0, up 99.92% from the prior year.
- Income from Continuing Operations was 101383000.0 for Q1 2026 at Scholar Rock Holding, down from 90904000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 6933000.0 in Q1 2022 to a low of 109904000.0 in Q2 2025.
- Historically, Income from Continuing Operations has averaged 60640882.35 across 5 years, with a median of 56832000.0 in 2024.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations surged 74.52% in 2022, then sank 484.29% in 2023.
- A 5-year view of Income from Continuing Operations shows it stood at 40428000.0 in 2022, then fell by 18.81% to 48032000.0 in 2023, then plunged by 38.33% to 66442000.0 in 2024, then slumped by 36.82% to 90904000.0 in 2025, then fell by 11.53% to 101383000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 101383000.0 (Q1 2026), 90904000.0 (Q4 2025), and 102151000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Scholar Rock Holding | 5.62 Bn | 5.14 Bn | - | -101.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -101.38 Mn |
| Dec 31, 2025 | -90.90 Mn |
| Sep 30, 2025 | -102.15 Mn |
| Jun 30, 2025 | -109.90 Mn |
| Mar 31, 2025 | -74.68 Mn |
| Dec 31, 2024 | -66.44 Mn |
| Sep 30, 2024 | -64.44 Mn |
| Jun 30, 2024 | -58.49 Mn |
| Mar 31, 2024 | -56.83 Mn |
| Dec 31, 2023 | -48.03 Mn |
| Sep 30, 2023 | -43.67 Mn |
| Jun 30, 2023 | -39.08 Mn |
| Mar 31, 2023 | -40.51 Mn |
| Dec 31, 2022 | -40.43 Mn |
| Sep 30, 2022 | -43.86 Mn |
| Jun 30, 2022 | -43.15 Mn |
| Mar 31, 2022 | -6.93 Mn |
| Dec 31, 2021 | -35.36 Mn |
| Sep 30, 2021 | -37.08 Mn |
| Jun 30, 2021 | -30.27 Mn |